Precision BioSciences — Q3 2026 Earnings Summary

Precision BioSciences reported a net loss of $7.6 million for the third quarter ended September 30, 2026, driven primarily by a non-cash gain on warrant liability adjustments. The company maintains a cash balance of $108 million as of September 30, 2026, which is projected to fund operations through 2028. Key clinical milestones include the enrollment of the first patient in the FUNCTION-DMD trial for Duchenne muscular dystrophy and the upcoming presentation of late-breaking data from the ELIMINATE-B trial for chronic hepatitis B at the AASLD Liver Meeting.